Format

Send to

Choose Destination
Haemophilia. 2015 Nov;21(6):784-90. doi: 10.1111/hae.12721. Epub 2015 May 20.

Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.

Author information

1
The Israeli National Hemophilia Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.
2
Department of Coagulation Disorders and Anemia, SHAT Joan Pavel, Sofia, Bulgaria.
3
CRD, CSL Behring, King of Prussia, PA, USA.
4
PRD, CSL Behring GmbH, Marburg, Germany.
5
Maggiore Hospital Policlinico, IRCCS Cà Granda Foundation, Milano, Italy.

Abstract

INTRODUCTION:

rIX-FP is a coagulation factor IX (recombinant), albumin fusion protein with more than fivefold half-life prolongation over other standard factor IX (FIX) products available on the market.

AIM:

This prospective phase II, open-label study evaluated the safety and efficacy of rIX-FP for the prevention of bleeding episodes during weekly prophylaxis and assessed the haemostatic efficacy for on-demand treatment of bleeding episodes in previously treated patients with haemophilia B.

METHODS:

The study consisted of a 10-14 day evaluation of rIX-FP pharmacokinetics (PK), and an 11 month safety and efficacy evaluation period with subjects receiving weekly prophylaxis treatment. Safety was evaluated by the occurrence of related adverse events, and immunogenic events, including development of inhibitors. Efficacy was evaluated by annualized spontaneous bleeding rate (AsBR), and the number of injections to achieve haemostasis.

RESULTS:

Seventeen subjects participated in the study, 13 received weekly prophylaxis and 4 received episodic treatment only. No inhibitors were detected in any subject. The mean and median AsBR were 1.25, and 1.13 respectively in the weekly prophylaxis arm. All bleeding episodes were treated with 1 or 2 injections of rIX-FP. Three prophylaxis subjects who were treated on demand prior to study entry had >85% reduction in AsBR compared to the bleeding rate prior to study entry.

CONCLUSION:

This study demonstrated the efficacy for weekly routine prophylaxis of rIX-FP to prevent spontaneous bleeding episodes and for the treatment of bleeding episodes. In addition no safety issues were detected during the study and an improved PK profile was demonstrated.

KEYWORDS:

factor IX; haemophilia B; haemostasis; pharmacokinetics; prophylaxis

PMID:
25990590
PMCID:
PMC4682460
DOI:
10.1111/hae.12721
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center